Ask AI
Back Back1

From Current Standards to Emerging Strategies: Rethinking the HNSCC Treatment Continuum

Start Activity
Clinical Thought
Clinical Thought Start Activity
See Activity Information

Released: August 19, 2026

See Activity Collection

Step 1 of 2

1 ClinicalThought 2 Complete Activity

In this activity, experts examine the evolving treatment continuum in head and neck squamous cell carcinoma (HNSCC), with a focus on how biologic factors, treatment setting, and therapeutic sequencing influence clinical decision-making. Expert perspectives address the prognostic and therapeutic implications of HPV status and PD-L1 expression; evidence from studies of immune checkpoint inhibition in locally advanced disease, including the differing results of concurrent, sequential, and perioperative strategies; and the role of pembrolizumab-based therapy in recurrent or metastatic HNSCC, where substantial unmet need remains despite improved outcomes. Faculty also review emerging EGFR-directed and bispecific approaches, including amivantamab, ficerafusp alfa, and petosemtamab, and consider how early response and durability data may inform future treatment strategies as these agents advance into later-phase trials. Together, these data highlight the importance of integrating biomarkers, disease setting, treatment sequencing, and emerging efficacy evidence when selecting therapy and planning care for patients with HNSCC.

Aarti Bhatia
Aarti Bhatia, MD, MPH
Deborah J. Wong
Deborah J. Wong, MD, PhD
HNSCC Treatment Continuum

Continue
Key Takeaways
  • For resectable HNSCC, perioperative strategies have shown greater promise than simply adding checkpoint inhibition concurrently to definitive chemoradiation.
  • EGFR-directed bispecific antibodies represent an emerging therapeutic strategy in patients with HPV-negative HNSCC and in recurrent/metastatic disease, with encouraging early-phase activity now being evaluated in phase III trials.

Head and neck squamous cell carcinoma (HNSCC) remains one of the more complex malignancies managed by healthcare professionals today because treatment decisions must balance disease control with preservation of function, quality of life, and long-term survivorship. Across the continuum from locally advanced disease to recurrent or metastatic HNSCC, the treatment landscape is evolving rapidly, and progress is no longer occurring within a single modality. Instead, the field is shifting to important advances in perioperative immunotherapy, targeted therapies, bispecific antibodies, and novel approaches designed to address populations that continue to have unmet needs. Below, expert faculty offer their perspectives on these emerging strategies, the evidence shaping current practice, and key questions that remain as the treatment paradigm continues to evolve.

Biology Still Matters

Aarti Bhatia, MD, MPH:
An important starting point in understanding HNSCC is distinguishing between human papillomavirus (HPV)–positive and HPV-negative disease. These are biologically and clinically distinct diseases. HPV-positive locally advanced disease is generally associated with more favorable outcomes, which has driven considerable interest in treatment deintensification strategies aimed at reducing long-term toxicity while maintaining disease control. By contrast, HPV-negative HNSCC generally carries a less favorable prognosis and remains an area of significant unmet need for more effective therapeutic approaches.

The distinction remains relevant even after recurrence. Real-world and clinical trial data continue to demonstrate that outcomes in recurrent or metastatic disease are relatively modest, particularly in HPV-negative tumors. Even with pembrolizumab-based treatment, which has transformed first-line management, we still see many patients experience progression within a relatively short time period.

For me, this reinforces an important clinical principle: HNSCC should not be approached as a single disease. HPV status, PD-L1 expression, resectability, prior treatment, performance status, and the likelihood of tolerating intensive therapy all influence how we think about treatment.

Immunotherapy Has Changed Practice, but Timing Appears Critical

Aarti Bhatia, MD, MPH:

The success of immune checkpoint inhibition in recurrent or metastatic HNSCC naturally led us to ask whether moving these agents earlier could improve cure rates. The answer has been more nuanced than many of us initially expected.

Several studies evaluating immune checkpoint inhibitors given concurrently with, or following, definitive therapy for locally advanced HNSCC did not demonstrate the improvements we had hoped to see. JAVELIN Head and Neck 100, KEYNOTE-412, NRG-HN004, GORTEC-REACH, and IMvoke010 collectively remind us that simply incorporating immunotherapy into an existing curative-intent regimen is not necessarily enough.

In addition, emerging data suggest that sequencing is an important determinant of clinical outcomes. The phase II HCC 15-132 study was particularly informative because sequential pembrolizumab after chemoradiation was associated with significantly better locoregional control than concurrent administration (P = .012). Although this was a relatively small study, it raised an important biological and clinical question about when immunotherapy may be most effective.

That question became even more relevant with the phase III KEYNOTE-689 trial. In resectable locally advanced HNSCC, perioperative pembrolizumab significantly improved event-free survival compared with standard treatment alone. The benefit was observed across prespecified PD-L1 populations and was particularly pronounced in tumors with higher PD-L1 expression. The treatment also reduced disease-recurrence events, including distant recurrence.

In my opinion, this represents an important evolution in how immunotherapy is used. The issue may not simply be whether immune checkpoint inhibition works in the curative-intent disease setting but rather where it is best positioned within the treatment sequence and in which patients.

Major Unmet Needs Remain in Recurrent and Metastatic Disease

Deborah J. Wong, MD, PhD:
In recurrent or metastatic HNSCC, KEYNOTE-048 established pembrolizumab-based therapy as a foundational first-line option. Pembrolizumab monotherapy improved overall survival (OS) in patients with PD-L1–expressing tumors (CPS ≥1), whereas pembrolizumab combined with chemotherapy improved OS in the overall study population.

Still, these results leave considerable room for improvement. Response rates remain limited with pembrolizumab monotherapy, and many patients may ultimately progress. Combinations such as nivolumab plus ipilimumab demonstrated durable responses in a subset of patients but did not significantly improve OS vs standard therapy in CheckMate 651.

EGFR-Directed Bispecific Antibodies May Expand Treatment Options

Deborah J. Wong, MD, PhD:
EGFR remains a biologically relevant target in HNSCC, but newer agents are attempting to move beyond traditional EGFR inhibition by simultaneously engaging additional pathways.

Amivantamab, which targets EGFR and c-MET, has shown encouraging activity in previously treated HPV-unrelated recurrent or metastatic disease. In OrigAMI-4, amivantamab monotherapy produced a blinded independent central review-assessed confirmed objective response rate (ORR) of 42%, whereas the combination of amivantamab and paclitaxel demonstrated even higher preliminary response rates (64%) in a small cohort of 11 patients.

Ficerafusp alfa takes a different approach by targeting EGFR and trapping TGF-β. In combination with pembrolizumab, early-phase data in HPV-negative, PD-L1–positive recurrent or metastatic disease showed a confirmed ORR of 54%, median duration of response of 21.7 months, and median OS of 21.3 months.

Petosemtamab, an EGFR x LGR5 bispecific antibody, has also demonstrated activity both as monotherapy in previously treated recurrent or metastatic HNSCC and in combination with pembrolizumab in the first-line PD-L1–positive setting. Patients with PD-L1–positive relapsed or metastatic HNSCC experienced a confirmed ORR of 63% when treated with petosemtamab plus pembrolizumab. These findings have led to ongoing phase III studies with these agents that should help determine whether these promising response rates translate into meaningful survival improvements.

What I find most encouraging is the broader direction of the field: We are beginning to combine immune modulation with more biologically targeted approaches rather than relying exclusively on cytotoxic chemotherapy.

Summary

Aarti Bhatia, MD, MPH:
The HNSCC treatment landscape is moving toward greater biological precision and more thoughtful treatment sequencing. Pembrolizumab remains central to recurrent or metastatic disease, and perioperative immunotherapy is reshaping curative-intent management for selected patients with resectable locally advanced disease. Furthermore, EGFR-directed bispecific antibodies and other targeted strategies may provide new options for patients whose disease remains difficult to treat.

For healthcare professionals, the challenge will be integrating these advances without losing sight of what matters most: maximizing cure when possible, extending survival when a cure is not achievable, preserving function, and minimizing treatment burden.

For a deeper discussion of these evolving treatment strategies and their implications for clinical practice, listen to the accompanying podcast featuring expert perspectives on the changing HNSCC treatment landscape.

Your Thoughts
What questions do you have related to recent changes in HNSCC management or emerging therapies? What would you like to learn more about? What are your biggest challenges in the care of patients with HNSCC?

Continue

Poll

1.

Has your practice adopted perioperative pembrolizumab for patients with resectable disease HNSCC?

Submit